Action Required: Password Reset on Next Login

As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.

To reset your password, please visit the Reset Password page.

We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Jun 29, 2023
Deals

Janssen says half pipeline value will come from outside 

What the last two years of BD reveal about the kind of innovation J&J is seeking, and where it’s finding opportunities 
BioCentury | Jun 6, 2022
Deals

Sale of programs to J&J leaves Yumanity as shell for Kineta reverse merger

Combined company to advance Seattle biotech’s cancer programs as Yumanity’s eight-year history in neurodegeneration comes to a close
BioCentury | Aug 25, 2020
Deals

Reverse merger offers Yumanity faster, less risky path to NASDAQ

Despite continued demand for biotech IPOs, Yumanity has opted to take a less traditional route to the public markets in a move that it views as more efficient and less risky.  On Monday, the
BioCentury | Nov 3, 2018
Product Development

New partners for NASH

New NASH targets and combinations will be in the spotlight at this year’s AASLD
BioCentury | Jun 14, 2018
Clinical News

After NASH readout, Galmed looks to Phase III

BioCentury | Jun 12, 2018
Clinical News

After NASH readout, Galmed looks to Phase III

Items per page:
1 - 10 of 36